Marshall Wace
BIIB icon

Marshall Wace’s Biogen BIIB Stock Holding History

Marshall Wace’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$821K Sell
3,800
-2,600
-41% -$497K ﹤0.01% 2302
2026
Q1 		$1.17M Buy
6,400
+6,200
+3,100% +$1.14M ﹤0.01% 2057
2025
Q4 		$35.2K Sell
200
-2,000
-91% -$327K ﹤0.01% 2800
2025
Q3 		$308K Buy
+2,200
New +$297K ﹤0.01% 2419

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace's BIIB Position: Q2 2026 in Review

Marshall Wace reduced its Biogen (BIIB) stake by 95% in Q2 2026, selling an estimated $41.6M and leaving 12,595 shares worth $2.72M. The position accounts for ﹤0.01% of the portfolio, ranked #1678.

Marshall Wace first reported a position in BIIB in Q3 2014 and has held it in 43 quarters since. The position peaked at $345M in Q4 2022. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Marshall Wace held 12,595 shares of Biogen worth $2.72M as of Q2 2026.
  • Marshall Wace sold 217,284 Biogen shares in Q2 2026, an estimated $41.6M.
  • Biogen made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1678 holding.
  • Marshall Wace first reported a position in Biogen in Q3 2014 and has held it in 43 quarters since.
  • Marshall Wace's Biogen position peaked at $345M in Q4 2022.
  • 1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.